← All trials
NCT07082205
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 2, 2025
- Primary completion
- Sep 30, 2026
- Completion date
- Apr 30, 2027
- First posted
- Jul 24, 2025
- Last posted
- Jul 24, 2025
- Enrollment
- 398
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LiverpoolLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of LiverpoolOfficial
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.